RBI
NBIX icon

Raiffeisen Bank International’s Neurocrine Biosciences NBIX Stock Holding History

Raiffeisen Bank International’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.4K Hold
400
– – ﹤0.01% 573
2026
Q1 		$52.7K Hold
400
– – ﹤0.01% 565
2025
Q4 		$47.4K Hold
400
– – ﹤0.01% 554
2025
Q3 		$56.2K Buy
+400
New +$54.2K ﹤0.01% 549

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Raiffeisen Bank International's NBIX Position: Q2 2026 in Review

Raiffeisen Bank International increased its Neurocrine Biosciences (NBIX) stake by 11% in Q2 2026, buying an estimated $202K and bringing the position to 13,864 shares worth $2.36M. The position accounts for 0.03% of the portfolio, ranked #279.

Raiffeisen Bank International first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.62M in Q4 2025. 439 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Raiffeisen Bank International held 13,864 shares of Neurocrine Biosciences worth $2.36M as of Q2 2026.
  • Raiffeisen Bank International bought 1,364 Neurocrine Biosciences shares in Q2 2026, an estimated $202K.
  • Neurocrine Biosciences made up 0.03% of Raiffeisen Bank International's portfolio in Q2 2026, its #279 holding.
  • Raiffeisen Bank International first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Raiffeisen Bank International's Neurocrine Biosciences position peaked at $2.62M in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Raiffeisen Bank International's 13F filing for Q2 2026, filed 3 Aug 2026.